Background
==========

Charcot-Marie-Tooth disease-5 (CMTX5, MIM 311070 \[[@B1],[@B2]\]), Arts syndrome (MIM 301835 \[[@B3],[@B4]\]) and X-linked nonsyndromic sensorineural deafness (DFN2; MIM 304500 \[[@B5]\]) present three clinically distinct but genetically allelic disorders, caused by reduced phosphoribosylpyrophosphate synthetase 1 (PRS1) activity due to *PRPS1* mutations \[[@B6]\]. Only three families with CMTX5 and two families Arts syndrome, respectively, have been reported worldwide so far \[[@B1],[@B3],[@B7]\]. Thus, evidence is still rare whether these two disorders are separate entities, or rather clusters on a phenotypic continuum of *PRPS1*-related disease. In addition, knowledge about intrafamilial variability and phenotypic manifestations in female carriers is limited.

Here, we report a family with a novel *PRPS1* missense mutation providing several new insights in PRS-I -hypoactivity disease. First, features of CMTX5 and Arts syndrome features can overlap within individuals, indicating an intraindividual continuum of these two disorders. Second, CMTX5/Arts and (prelingual, severe) DFN2 can present within one and the same family, revealing an intrafamilial continuum of these disorders. Third, the respective phenotypic presentation along the continuous spectrum of *PRPS1*-related disease seems to be determined by the exact *PRPS1* mutation and the degree of residual PRS-I enzyme activity, the latter being largely influenced by the degree of skewed X-inactivation.

Methods
=======

The index patient, his sister and his mother were investigated by (i) detailed clinical examination by a specialist in rare neurogenetic disorders, (ii) routine laboratory serum tests including uric acid analysis, (iii) enzymatic analyses of PRS-I activity in erythrocytes (for methodological details, see Additional file [1](#S1){ref-type="supplementary-material"}), and (iv) *PRPS1* DNA sequence analysis (for methodological details, see Additional file [2](#S2){ref-type="supplementary-material"}). Additionally, the index patient and his sister were assessed by (v) nerve conduction studies, (vi) ophthalmological funduscopy, and (vii) routine brain magnetic resonance imaging (MRI).

The frequency of the identified *PRPS1* variant was determined in more than 4,250 X-chromosomes of European control individuals with unrelated phenotypes analyzed by exome sequencing (for methodological details, see \[[@B8]\]). In addition, the frequency of the change was assessed in the exome variant server (EVS) of the National Heart, Lung, and Blood Institute GO Exome Sequencing Project (Seattle, WA, USA; URL: evs.gs.washington.edu/EVS/) with the corresponding nucleotide positions being analyzed in \>8,000 European and \>4,000 African American alleles, and in the Database of Single Nucleotide Polymorphisms (dbSNP; Bethesda: National Center for Biotechnology Information, National Library of Medicine \[dbSNP Build ID: 138\]; available from: <http://www.ncbi.nlm.nih.gov/SNP/>). *In-silico* predictions of the pathogenicity of genetic variants were performed using PolyPhen-2 \[[@B9]\], SIFT \[[@B10]\] and MutationTaster \[[@B11]\]. The effect of the amino acid change on the structure of *PRPS1* was predicted using the crystal structure of human *PRPS1* from \[[@B12]\] (PDB entry 2H06; <http://www.pdb.org/>) as described before \[[@B4]\]. X-inactivation patterns in female *PRPS1* mutation carriers were tested by using the highly polymorphic (CAG)n region of the human androgen receptor gene (HUMARA locus) after methylation-sensitive digestion with HpaII, as described previously \[[@B13]\]. This study was carried out in compliance with the Helsinki Declaration, and approved by the Institutional Review Board of the University of Tübingen, reference number 598/20118O1.

Consent
-------

Written informed consent was obtained from the patients for the publication of this report and any accompanying images.

Results
=======

Clinical assessment
-------------------

A 36 year-old male patient from non-consanguineous German parents (subject II-2; for pedigree, see Figure [1](#F1){ref-type="fig"}A; for clinical details see Table [1](#T1){ref-type="table"}) presented with prelingual hearing loss since birth, recurrent severe infections from age 6 to 8 years with subsequent partially remitting bulbar paresis and flaccid tetraparesis which never fully resolved, and progressive visual loss due to optic atrophy since age 12 years (current vision at age 36 years: 0.1 right eye, 0.3 left eye). Gait and trunk ataxia started at age 30, leading to a dependency on a walking-frame at age 34 years. Disease severity on the Scale for the Assessment and Rating of Ataxia (SARA) yielded 14 out of 40 points \[[@B14]\]. Behavioural and mental disturbances started at age 16 years, yet the patient was still able to finish secondary school. Already at this time, the patient showed a severely reduced attention span, mental rigidity, low frustration tolerance and aggression to persons including family members. He was unable to perceive and describe his own physical problems during medical visits, rejected social contacts, and neglected the need for medical and rehabilitative treatment. In the following years, he developed attacks of verbal and physical aggression, e.g. repeatedly pulling his mother down to the floor by her hairs at age 35 years. Cycles of aggressive and impulsive behaviour alternated rapidly with cycles of infantile-regressive behaviour, e.g. shouting and crying at age 35 years when confronted with the need for a medical blood sampling. The lack of compliance and cooperative behaviour led to the cessation of examinations required for pre-surgery evaluation for cochlea implants. His cognitive capacities and insight at age 36 years seemed to be below the stage of an adolescent, but no formal neuropsychological testing was possible given his severe hearing and visual impairments and lack of cooperative behaviour. The combined load of physical, mental and behavioural disturbances required an institutionalization in long-term care since age 35 years. Cerebral MRI demonstrated mild cerebellar and parietal cortical atrophy (Figure [2](#F2){ref-type="fig"}A,B). Nerve conduction studies showed florid predominant axonal sensorimotor neuropathy (Table [1](#T1){ref-type="table"}) with positive sharp waves on EMG of the tibial anterior muscle. Repeated lab testing revealed markedly increased serum creatinkinase (\>1000 U/l, ref \< 190 U/l), probably caused by progressive muscle cell turnover due to florid peripheral neuropathy. In addition, liver transaminases were constantly mildly elevated (AST 60 U/l; ref \<50 U/l; ALT 90 U/l; ref \< 50 U/l), with abdominal sonography showing no structural liver abnormalities.

![**Pedigree, PRS enzymatic activity, conservation, and predicted protein structural effects of the novel Gln277Pro*PRPS1*variant. (A)** Pedigree of the family shows maternal inheritance of the *PRPS1* mutation with variable phenotypic severity of disease, reaching from an unaffected state in the mother (I-1) to a mildly affected DFN2 phenotype in the sister of the index patient (II-1) to a severe Arts/CMTX5 overlap syndrome in the index patient (II-2). **(B)** The severity of the phenotype correlated with the PRS1 enzymatic activity in erythrocytes. **(C)** Protein alignment demonstrates high conservation for the mutated amino acid position 277 in the PRPS1 protein across mammals and non-mammals. **(D)** PRS1 catalyses the synthesis of phosphoribosylpyrophosphate (PRPP) from ribose 5-phosphate (R5P) and ATP, and is thought to be physiologically functional as a hexamer, consisting of three homodimers arranged in a propeller-like shape. In this hexamer, the N-terminal domains are located at the centre and the C-terminal domains at the outside. **(E)** Gln277 is predicted to interact with Gly251, which is close proximity to the R5P binding site The p.Gln277Pro change will result in a loss of this hydrogen bonding interaction potentially destabilizing the region surrounding the R5P binding site, thus affecting the *PRPS1* catalytic active site.](1750-1172-9-24-1){#F1}

###### 

**Clinical findings and further investigations in*PRPS1*Gln277Pro mutation carriers**

  **Subject**                                                  **II.2**                                                                                                                        **II.1**                                        **I.2**
  ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------- ----------------------------
  Gender                                                       m                                                                                                                               f                                               f
  Phenotypic cluster                                           CMTX5/Arts                                                                                                                      DFN2                                            None
  Current age                                                  36                                                                                                                              42                                              66
  Age of onset first symptom                                   Congenital, hearing loss                                                                                                        Congenital, hearing loss                        None
  **Neurological**                                                                                                                                                                                                                             
  Mental retardation                                           (+) progressive aggressive, childish behavior, starting at age 18                                                               \-                                              \-
  Ataxia (age of onset)                                        +, 30 years                                                                                                                     \-                                              \-
  Severity of ataxia (SARA score)                              14 out of 40                                                                                                                    1 out of 40                                     0 out of 40
  Delayed motor development                                    \-                                                                                                                              \-                                              \-
  Loss of deep tendon reflexes                                 \+                                                                                                                              \-                                              \-
  Hearing loss (age of onset)                                  +, congenital                                                                                                                   +, congenital                                    
  Optic atrophy (age of onset)                                 12                                                                                                                              \--                                             \-
  **Uric acid overproduction**                                                                                                                                                                                                                 
  Gout                                                         \-                                                                                                                              \-                                              \-
  Kidney stones                                                \-                                                                                                                              \-                                              \-
  Renal failure                                                \-                                                                                                                              \-                                              \-
  Serum uric acid (ref 3.4-7.0 mg/dl)                          4.3 mg/dl                                                                                                                       4.4 mg/dl                                       4.2 mg/dl
  **Hematopoetic**                                                                                                                                                                                                                             
  Recurrent infections                                         (+), only from age 6 to 8 years                                                                                                 \-                                              \-
  Anemia                                                       \-                                                                                                                              \-                                              \-
  **Other**                                                                                                                                                                                                                                    
  Short stature                                                \-                                                                                                                              \-                                              \-
  Self-injury                                                  \-                                                                                                                              \-                                              \-
  Early death                                                  \-                                                                                                                              \-                                              \-
  **Lab, electrophysiology and MRI investigations**                                                                                                                                                                                            
  Nerve conduction studies                                                                                                                                                                                                                      
  -Sensory nerve conduction                                    Sur: no SNAP; Rad: no SNAP                                                                                                      Sur: normal, Rad: normal                        n.d.
  Sural or radial nerve                                                                                                                                                                                                                        
  -Motor nerve conduction                                      Tib: borderline MNCV (40 m/s; ref \> 40 m/s); Uln: reduced CMAP (2.1 mV; ref: \> 4 mV); reduced MNCV (36 m/s; ref: \> 50 m/s)   Tib: normal; Uln: normal                         
  Tibial or ulnar nerve                                                                                                                                                                                                                        
  MRI                                                          Mild cerebellar and parietal cortical atrophy                                                                                   Mild cerebellar and parietal cortical atrophy   n.d.
  Serum creatinkinase (ref \<180 U/l)                          1168 U/l                                                                                                                        141U/l                                          196 U/l
  PRS-I enzyme activity (ref 0.41-1.46 nmol/(min.mg protein)   \<0.005 nmol/(min.mg protein)                                                                                                   0.1 nmol/(min.mg protein)                       1.04 nmol/(min.mg protein)

This table was designed to show not only those clinical symptoms that are present, but also those that are absent in this index family, yet common in other *PRPS1* patients. The features were selected and extended from de Brouwer et al., 2010 \[[@B6]\]. Legend: m, male; f, female; n.d., not done; ref, reference value; SARA, scale for the Assessment and Rating of Ataxia, reaching from 0 to 40, with higher scores indicating more severe ataxia; scores \< 3 points are considered unspecific. Sur = sural; Rad = radial; Tib = tibial, Uln = ulnar; SNAP = sensory nerve action potential; SNCV = sensory nerve conduction velocity; CMAP = compound muscle action potential; MNCV = motor nerve conduction velocity; MRI, magnetic resonance imaging.

![**Brain magnetic resonance imaging (MRI) of the two affected siblings.** MRI shows diffuse parietal atrophy (arrows in **A**, **C**) and mild cerebellar atrophy (arrows in **B**, **D**) in the index patient II-2 at age 31 years (upper row) as well as in his sister II-1 at age 38 years (lower row) (**A**, **C** T1 axial; **B**, FLAIR coronar; **D** T2 axial).](1750-1172-9-24-2){#F2}

His sister (subject II-1; Figure [1](#F1){ref-type="fig"}A) had developed prelingual sensorineural hearing loss in the first years of life, without any further signs of neurological dysfunction at current age of 42 years. This phenotype is fully compatible with the diagnosis of X-linked non-syndromic sensorineural hearing loss (DFN2) \[[@B5]\]. Her MRI showed discrete parietal and cerebellar atrophy as well (Figure [2](#F2){ref-type="fig"}C,D). The mother of the two subjects (subject I-1) did not show any hearing deficit or neurological dysfunction at the current age of 66 years. Uric acid in serum was normal in all three subjects (for an overview of all clinical and lab details, see Table [1](#T1){ref-type="table"}).

Serum biomarker and genetic analyses
------------------------------------

Based on the initial clinical assumption of an autosomal-recessive ataxia, the index patient was assessed by extensive serum testing for biomarkers indicative of recessive ataxias (alpha-feto protein, lactate, vitamin E, very long chain fatty acids, phytanic acid, coeruloplasmin, cholesteanol, lysosomal enzymes, carbohydrate-deficient transferrin, quantitative assessment of amino acids) \[[@B15]\], and genetic testing of *FRDA*, *POLG*, *PEO1/Twinkle*, *WFS1*, and *ABHD12*. All results were normal. Sequencing of *PRPS1* revealed a novel hemizygous c.830A \> C, p.Gln277Pro variant changing a highly conserved amino acid residue (PhyloP score 4.6; Figure [1](#F1){ref-type="fig"}C), predicted to be damaging by all *in silico* predictions (PolyPhen-2 score: 0.991; SIFT score: 0.01; MutationTaster: disease causing), and not found in 4,200 ethnically-matched control X-chromosomes or in the 6,500 exomes (= 10,562 alleles) of the NHLBI Exome Variant Server (EVS). The same variant was identified in the sister (II-1) and the mother (I-1) of the index patient in a heterozygous state (for electropherograms, see Additional file [3](#S3){ref-type="supplementary-material"}).

Protein structural effects of the PRPS1 mutation
------------------------------------------------

Gln277 is located in the C-terminal domain of *PRPS1* and is close to the catalytic active site, which consists of an ATP binding site and a ribose-5-P binding site (Figure [1](#F1){ref-type="fig"}D). The p.Gln277Pro change results in two sequential prolines, which very likely disrupts the alpha-helical structure of this short helical segment and destabilizes the C-terminal *PRPS1* domain. In addition, Gln277 interacts with Gly251, which is close proximity to the R5P binding site (Figure [1](#F1){ref-type="fig"}E). The p.Gln277Pro change will result in a loss of this hydrogen bonding interaction potentially destabilizing the region surrounding the ribose-5-P binding site, thus affecting the *PRPS1* catalytic active site. When comparing the protein structural effects of all known *PRPS1* mutations and their relations to *PRPS1*-phenotypic clusters, the p.Gln277Pro (Q277P) mutation falls in between CMTX5 and Arts syndrome *PRPS1* mutations. Like other Arts syndrome mutations (and in contrast to CMTX5 *PRPS1* mutations), it is predicted to disrupt the local *PRS-I* structure. However, unlike the other Arts syndrome mutations and in line with the CMTX *PRPS1* mutations, it is not predicted to disturb the allosteric site II or to affect the dimer interface (Table [2](#T2){ref-type="table"}).

###### 

**Predicted structural effects of known*PRPS1*mutations**

  **Mutation**               **Disturbance of local structure**   **Affecting dimer interface**   **Affecting trimer interface**   **Disturbance of ATP binding site**   **Disturbance of allosteric site I**   **Disturbance of allosteric site II**   **Neuropathy**
  ------------------------- ------------------------------------ ------------------------------- -------------------------------- ------------------------------------- -------------------------------------- --------------------------------------- ----------------
  **PRS-I superactivity**                                                                                                                                                                                                                                      
  p.D52H                                     \+                                \-                               \+                                 \-                                     \+                                     \-                           \-
  p.N114S                                    \-                                \+                               \+                                 \-                                    +/-                                     +/-                          \+
  p.L129I                                    \+                                \-                               \-                                 \-                                     \-                                     \+                           \+
  p.D183H                                    \-                                \+                               \-                                 \-                                    +/-                                     +/-                          \+
  p.A190V                                    \+                                \+                               \-                                 \-                                    +/-                                     +/-                          \+
  p.H193L\*\*                                \-                                \+                               \-                                 \-                                    +/-                                     +/-                          \-
  p.H193Q                                    \-                                \+                               \-                                 \-                                    +/-                                     +/-                          \+
  p.V142L                                    \+                                \+                               \-                                 \-                                     \-                                     \+                           \+
  **Arts syndrome**                                                                                                                                                                                                                                            
  p.Q133P                                    \+                                \+                               \-                                 \+                                    +/-                                     \+                           \+
  p.L152P                                    \+                                \+                               \-                                 \+                                    +/-                                     \+                           \+
  **p.Q277P**                              **+**                              **-**                          **+/-**                              **+**                                 **-**                                   **-**                       **+**
  **CMTX5**                                                                                                                                                                                                                                                    
  p.E43D                                     \-                                \-                               \+                                 \+                                     \+                                     \-                           \+
  p.M115T                                    \-                                \-                               \+                                 \+                                     \+                                     \-                           \+
  p.A121G                                    \+                                \-                              +/-                                 +/-                                   +/-                                     \-                           \+
  **DFN2**                                                                                                                                                                                                                                                     
  p.D65N                                   **-**                              **-**                           **+**                               **-**                                   \-                                     \-                           ?
  p.A87T                                   **+**                              **-**                           **-**                               **-**                                   \-                                     \-                           ?
  p.I290T                                  **+**                              **-**                           **-**                               **-**                                   \-                                     \-                           ?
  p.G306R                                  **-**                              **-**                           **+**                               **-**                                   \-                                     \-                           ?

When comparing the protein structural effects of all known PRPS1 mutations and their relations to PRPS1-phenotypic clusters, the p.Gln277Pro mutation falls in between CMTX5 and Arts syndrome *PRPS1* mutations. Like other Arts syndrome mutations (and in contrast to CMTX5 *PRPS1* mutations), it is predicted to disrupt the local PRS-I structure. However, unlike the other Arts syndrome mutations (and in line with other CMTX *PRPS1* mutations), it is not predicted to disturb the allosteric site II or to affect the dimer interface. This table was selected, updated and extended from de Brouwer et al., 2010 \[[@B6]\]. Please see here also for further references \[[@B6]\]. \*\*This mutation was found in a female patient.

Enzyme activity
---------------

PRS-I activity was not detectable in erythrocytes the index patient II-2 (\<0.005 nmol/\[min.mg protein\]; reference value: 0.41-1.46 nmol/\[min.mg protein\]), reduced to 0.10 nmol/\[min.mg protein\] in his sister (II-1), and normal in their mother (I-1; 1.04 nmol/\[min.mg protein\]) (Figure [1](#F1){ref-type="fig"}B).

X- chromosome inactivation (XCI)
--------------------------------

XCI was extremely skewed (defined as ratio \> 90%:10% \[[@B16]\]) in II-1 (94%:6%), but only moderately skewed in I-1 (80%:20%).

Discussion
==========

Here we report a family with a novel *PRPS1* mutation which provides new insights in *PRPS1*-related disease. The index patient (subject II-2) showed an overlapping phenotype combining features of both CMTX5 and (mild, relatively late-onset) Arts syndrome. Prelingual hearing loss, optic atrophy with onset in the teens and severe sensorimotor neuropathy are part of the classical CMTX5 trias \[[@B2]\]. However, recurrent infections in childhood leading to acute deteriorations of slowly progressive muscle weakness, severe ataxia leading to walker-dependency, mild to moderate mental and behavioural deficits, and institutionalization in homes for physically and mentally handicapped are all features not reported in previous CMTX5 subjects, but known from subjects with Arts syndrome (though usually in a more severe early-onset form) \[[@B3],[@B17]\]. This shows that CMTX5 and Arts syndrome can overlap within one and the same individual, thus indicating a continuous spectrum of PRS1- hypoactivity disease. This finding corroborates and extends the recent observation from one individual with PRS-I superactivity who showed not only signs of PRS-I superactivity syndrome, but also of Arts syndrome \[[@B18]\]. Taken together, these findings indicate that both PRS1 superactivity and PRS-I hypoactivity disorders form a continuous gradual spectrum of disease.

The notion of a continuous disease spectrum of PRS1-hypoactivity disorders is further supported by our observation that a CMTX5/Arts overlapping phenotype can co-occur within the same family as a DFN2 phenotype (subject II-1), demonstrating an intrafamilial continuum of these three clusters of PRS-I hypoactivity diseases. So far, CMTX5, Arts syndrome and DFN2 were only reported in different families, not within the same family \[[@B6]\]. An earlier report already indicated that some subjects can present with an only incomplete presentation of a PRPS1 disease cluster (e.g. absence of optic atrophy in CMTX5 subjects \[[@B7]\]). Taken together, these findings suggest a continuous spectrum of *PRPS1* disease features, where hearing loss, peripheral neuropathy, optic atrophy, ataxia, cognitive deficits and recurrent infections are central, yet variable phenotypic features. Along this spectrum, the established *PRPS1* disease clusters are not separate entities, but endophenotypes on a phenotypic continuum.

Female carriers in families with Arts syndrome were known to sometimes exhibit some hearing impairment later in life (age \>20 years) combined with ataxia and neuropathy \[[@B3],[@B19]\]; yet prelingual hearing loss starting at birth - as observed in subject II-1 - has not yet been described in these families. Female carriers in families with CMTX5 are noted to be asymptomatic \[[@B1]\]. Our findings indicate that these current notions and corresponding counselling recommendations of female carriers in families with CMTX5 \[[@B1]\] or Arts syndrome \[[@B3]\] should be revised: female carriers in families with these phenotypic clusters can show symptoms already very early in life, leading to substantial impairment in everyday social life.

How might this intrafamilial continuum of *PRPS1* disease clusters be explained? Our results indicate that the respective phenotypic presentation seems to be determined by (1.) the exact *PRPS1* mutation (in males) and (2.) the residual enzyme activity, which in turn is largely influenced by the degree of skewed X-inactivation (in females). The predicted structural effects of the p.Gln277Pro mutation fall in between those of the CMTX5 and Arts syndrome *PRPS1* mutations (Table [2](#T2){ref-type="table"}), thus explaining the CMTX/Arts syndrome overlapping phenotype in the male index patient II-2. PRS-I enzyme activity was not detectable in this male subject with the most complex and severe phenotype, while it was moderately reduced in his sister II-1 with a nonsyndromic hearing loss phenotype (DFN2), and normal in his unaffected mother I-1. (Figure [1](#F1){ref-type="fig"}B). The lack of detectable PRS-I activity in subject II-2 might explain why his phenotypic presentation included components of the Arts cluster, as absence of PRS-I activity has already been reported for patients with a pure Arts phenotype \[[@B4]\]. The residual PRS-I activity in the female carriers (I-1; II-1) might be explained by compensation through the second (intact) X chromosome. PRS-I activity was lower in subject II-1 than in subject I-1, most likely due to severely skewed X-chromosome inactivation which was observed in this subject. Alternatively, tissue-specific control of other genetic and epigenetic mechanisms might explain the differences in PRS1 activity between I-1 and II-1, e.g. the regulation of *PRPS1* by microRNA-376 \[[@B17]\] and difference in expression levels and function of the other three PRS isoforms \[[@B6]\]. Our finding of a clinico-enzymatic correlation between enzymatic activity and disease severity indicates that PRS-I activity may serve as a blood biomarker for *PRPS1* disease and may help to corroborate pathogenicity of novel *PRPS1* variants of unknown significance. It also suggests that it might serve as an interesting readout and surrogate parameter for treatment efficacy.

So far, cerebral MRI abnormalities have been observed neither in CMTX5 nor in Arts syndrome \[[@B3]\], yet such abnormalities are likely given the wide range of clinical central nervous abnormalities in *PRPS1*-disorders, in particular in Arts syndrome. Here we show that mild signs of cerebellar and parietal atrophy can be seen in both subject II-2 and subject II-1, thus providing first evidence for structural central nervous system damage in *PRPS1*- disease. As atrophy is very mild, it might have been present also in previous *PRPS1* subjects, yet not been recognized. Our finding of a subject with adolescent-onset ataxia with neuropathy, optic atrophy, hearing loss, and mild atrophy of the cerebellum without evidence of neurological disease in the parental generation places *PRPS1*-disease in the differential diagnosis of many adult-onset autosomal-recessive and mitochondrial ataxias where such findings are common and which might be mimicked by *PRPS1*-disease. This differential diagnosis includes e.g. OPA3/Type III methylglutaconic aciduria (MIM 606580), OPA1 (MIM 605290) or Wolfram Syndrome (MIM 606201).

Conclusions
===========

Our findings indicate that CMTX5, Arts syndrome and DFN2 are phenotypic clusters on a continuous intraindividual and intrafamilial spectrum of PRPS1-disease. The respective phenotypic presentation seems to depend on the exact *PRPS1* mutation and the residual enzyme activity and skewed X-inactivation, respectively.
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